RV144
came out yesterday on the news, but since I had nothing to do with any petty famosillos, not given the hype it deserves, at least for my taste, for a vaccine against AIDS is not got all day. Vale, only 31% immunized and vaccinated, but better than nothing.
The vaccine, called the original name of RV144, so that is temporary, was tested on 16,402 Thai volunteers between 18 and 30 years with an average risk of infection. Half were given 6 doses of 2 vaccines in 2006, and the other half a placebo. 3 years after blood tests were performed for the virus. Vaccinated half were infected 51 people and another, 74. To the surprise of people in white coats carrying out the study, all were infected with the same amount of virus. Typically a vaccine, but only partially protects the viral load decreases.
This suggests that the new vaccine will not produce Ab (antibodies) against the virus *. Instead, it seems that Ab binding form that fit into any surface protein effector cells, a type of white blood cell that attacks the virus, to empower them.
In any case, the mechanism of the vaccine does not mimic the defenses of those who do not get sick despite being infected. For some strange metaphysical reason not able to replicate the virus, reducing viral load. If you knew what immune response mediated this effect, it would greatly progress in the fight against AIDS.
Returning to the subject: what the hell is exactly the RV144?
Well, the RV144 is the combination of 2 vaccines designed through genetic engineering and had not worked separately in humans: ALVAC and AIDSVAX. The ALVAC virus containing canarypox three HIV genes attached. AIDSVAX, meanwhile, contains a genetically engineered version of a protein on the surface of HIV. Combined
both have the RV144 vaccine, although only have an efficiency of 31% represents a door to hope, to the "spes" after 20 years of fruitless investigations. At least now we know the vaccine against HIV is possible.
More and better worded here, here and here. Choose which give you more rage.
0 comments:
Post a Comment